Uday Baldota

Baldota, who has also been nominated to Taro's board of directors, is expected to begin his role as CEO on or about April 1, 2017, and will focus solely on the Taro business.

Integration costs to continue into FY16: Sun Pharma

Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking remediation plans for all Ranbaxy facilities.

Merger with Ranbaxy might get delayed: Sun CFO Baldota

The pharma major is hopeful of maintaining its revenue growth guidance of 13-15 percent for FY15 though the margins may get impacted marginally.

Sun Pharma says seeks to enter Japan generics market

Sun also sought to take full control of its US-listed Israeli unit Taro Pharmaceutical Industries Ltd , but the deal was terminated last year after a long-drawn battle.

Margins may cool, but revenue growth seen solid: Sun Pharma

Uday Baldota, Senior Vice President-Finance & Accounts, Sun Pharma cautioned that the jump in operating margin to 44 percent seen during the quarter may not be sustained.

Sun Pharma to continue holding stake in Taro, says VP Fin

Uday Baldota, Senior Vice President-Finance & Accounts, Sun Pharma said the company will continue to hold stake in Taro despite their termination of the merger agreement.

Merck JV will earn revenues in a few years, says Sun Pharma

In an exclusive interview with CNBC-TV18, Uday Baldota of Sun Pharma says the company saw significant growth in Sun Pharma’s standalone numbers, while as well "Taro reported strong margins this quarter." The leading drugmaker discloses that the company is "bearing additional costs for some non-revenue generating businesses."

Sun Pharma eyes revenue growth of 28-30% in FY12

Sun Pharmaceutical is eyeing revenue growth of 28-30% in FY12, said Uday Baldota of Sun Pharma. In an interview to CNBC-TV18, Baldota said that Taro Pharmaceutical Industries reported strong margins this quarter.